Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant
Por:
Camacho J, Giménez E, Albert E, Zulaica J, Álvarez-Rodríguez B, Torres I, Rusu L, Burgos JS, Peiró S, Vanaclocha H, Limón R, Alcaraz MJ, Sánchez-Payá J, Díez-Domingo J, Comas I, Gonzáles-Candelas F, Geller R and Navarro D
Publicada:
1 ene 2023
Ahead of Print:
1 nov 2022
Resumen:
Studies investigating the cumulative incidence of and immune status against SARS-CoV-2 infection provide valuable information for shaping public health decision-making. A cross-sectional study on 935 participants, conducted in the Valencian Community (VC), measuring anti-SARS-CoV-2-receptor binding domain-RBD-total antibodies and anti-Nucleocapsid (N)-IgGs via electrochemiluminescence assays. Quantitation of neutralizing antibodies (NtAb) against ancestral and Omicron BA.1 and BA.2 variants and enumeration of SARS-CoV-2-S specific-IFN gamma-producing CD4(+) and CD8(+) T cells was performed in 100 and 137 participants, respectively. The weighted cumulative incidence was 51.9% (95% confidence interval [CI]: 48.7-55.1) and was inversely related to age. Anti-RBD total antibodies were detected in 97% of participants; vaccinated and SARS-CoV-2-experienced (VAC-ex; n = 442) presented higher levels (p < 0.001) than vaccinated/naive (VAC-n; n = 472) and nonvaccinated/experienced (UNVAC-ex; n = 63) subjects. Antibody levels correlated inversely with time elapsed since last vaccine dose in VAC-n (Rho, -0.52; p < 0.001) but not in VAC-ex (rho -0.02; p = 0.57). Heterologous booster shots resulted in increased anti-RBD antibody levels compared with homologous schedules in VAC-n, but not in VAC-ex. NtAbs against Omicron BA.1 were detected in 94%, 75%, and 50% of VAC-ex, VAC-n and UNVAC-ex groups, respectively. For Omicron BA.2, the figures were 97%, 84%, and 40%, respectively. SARS-CoV-2-S-reactive IFN-gamma T cells were detected in 73%, 75%, and 64% of VAC-ex, VAC-n and UNVAC-ex, respectively. Median frequencies for both T-cell subsets were comparable across groups. In summary, by April 2022, around half of the VC population had been infected with SARS-CoV-2 and, due to extensive vaccination, displayed hybrid immunity.
Filiaciones:
Camacho J:
Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
Giménez E:
Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
Albert E:
Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
Zulaica J:
Institute for Integrative Systems Biology (I2SysBio), University of Valencia-CSIC, 46980, Valencia, Spain
Álvarez-Rodríguez B:
Institute for Integrative Systems Biology (I2SysBio), University of Valencia-CSIC, 46980, Valencia, Spain
Torres I:
Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
Rusu L:
Institute for Integrative Systems Biology (I2SysBio), University of Valencia-CSIC, 46980, Valencia, Spain
Burgos JS:
General Directorate of Research and Healthcare Supervision, Department of Health, Valencia Government, Valencia, Spain
:
Foundation for the promotion of health and biomedical research of the Valencian Community (FISABIO), Valencia, Spain
:
General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain
Limón R:
General Directorate of Healthcare. Department of Health, Valencian Government, Valencia, Spain
Alcaraz MJ:
Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
Sánchez-Payá J:
Preventive Medicine Service, Alicante General and University Hospital, Alicante, Spain
Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain
:
Foundation for the promotion of health and biomedical research of the Valencian Community (FISABIO), Valencia, Spain
:
Biomedicine Institute of Valencia, Spanish Research Council (CSIC)
CIBER in Epidemiology and Public Health, Spain
Joint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain
:
Institute for Integrative Systems Biology (I2SysBio), University of Valencia-CSIC, 46980, Valencia, Spain
CIBER in Epidemiology and Public Health, Spain
Joint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain
Geller R:
Institute for Integrative Systems Biology (I2SysBio), University of Valencia-CSIC, 46980, Valencia, Spain
Navarro D:
Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain
Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain
FISABIO SALUD PÚBLICA - INVESTIGACIÓN EN VACUNAS, Valencia, Spain
hybrid, Green Submitted, Green Published
|